Columbia University researchers have developed a technique to enhance CAR T cell therapy in solid tumors by engineering E. coli bacteria that naturally accumulate in solid tumors. The bacteria are engineered to interact with tumor cells, deposit a synthetic antigen, and are then targeted by CAR T cells. This could expand the variety of cancers that can be treated using T cell therapy and enhance tumor cell killing effects. The CAR-T technology system may be universal, treating any solid tumor, without the need to customize the system for each tumor type or patient. This has been published in the journal Science: Probiotic-guided CAR-T cells for solid tumor targeting.
Source link
Bacteria Tag Team Tumors with T Cells
